Nanexa AB (publ) (STO:NANEXA)

Market Cap	1.21B +229.4%
Revenue (ttm)	33.86M +104.8%
Net Income	-24.56M
EPS	-0.14
Shares Out	191.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,122,843
Open	5.85
Previous Close	5.82
Day's Range	5.84 - 6.36
52-Week Range	1.40 - 6.33
Beta	1.74
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 17
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NANEXA

Financial Performance

In 2025, Nanexa AB's revenue was 36.15 million, an increase of 48.39% compared to the previous year's 24.36 million. Losses were -11.39 million, -54.27% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error